NL-OMON45212已完成不适用
Effects of aldosterone antagonism on microvascular function in obese individuals - Aldosterone antagonism and microvascular function
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Age 40-65 years
- •- Caucasian (because of ethnic differences in microvascular function, vascular stiffness, and the prevalence of cardiovascular disease and associated risk factors)
- •- Waist circumference > 102 cm (men)/> 88 cm (women)
- •- High-normal blood pressure (office blood pressure: 130/85 * 139/89 mm Hg) or stage I/II hypertension (office blood pressure: 140/90 mm Hg * 179/109 mm Hg; 24h ABPM: 125/80 * 169/99 mm Hg)
排除标准
- •- Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death)
- •- Diabetes mellitus/impaired fasting glucose (fasting glucose values > 6.1 mmol/L), because not only diabetes, but also intermediate hyperglycaemia has been associated with microvascular disease, which impedes the distinction between cause and consequence of disturbances in glucose metabolism in the concerning individuals
- •- Grade 3 hypertension (office blood pressure: > 180/110 mm Hg; ABPM > 170/100 mm Hg) in order not to expose these individuals to unnecessary risks by interrupting or postponing antihypertensive treatment
- •- Unstable or severe pulmonary disease
- •- Unstable or severe thyroid disorders
- •- Inflammatory diseases
- •- Alcohol use > 2 U/day (women)/> 3 U/day (men)
- •- Use of glucose-lowering medications, because of possible interference with microvascular function
- •- Use of corticosteroids (have also affinity for the mineralocorticoid receptor; can decrease the antihypertensive effect of Eplerenone), medication known to inhibit or induce CYP3A4 (possible interference with metabolism of Eplerenone), lithium (possible reduction of lithium excretion when used simultaneously with Eplerenone) , and tricyclic antidepressants or antipsychotic medication (risk of orthostatic hypotension when used simultaneously with Eplerenone), and regular use (weekly or several times a week) of NSAIDs (risk of acute renal dysfunction and disturbance of electrolyte excretion when used simultaneously with Eplerenone)
- •- Plasma potassium levels < 3.2 mmol/L or > 5 mmol/L
- •- eGFR < 60 mL/min
- •- Impairment of hepatic function
- •- Pregnancy or lactation
研究者
相似试验
已完成
不适用
Aldosterone-induced microvascular dysfunction as a cause of salt-sensitivity in obesity?insulin resistance/decreased sensitivity for insulinsalt-sensitivity of blood pressure1001842410057166NL-OMON40283Medisch Universitair Ziekenhuis Maastricht40
已完成
不适用
Does aldosterone blockade improve endothelial dysfunction in patients with coronary artery disease but without heart failure?Coronary artery diseaseCirculatory SystemISRCTN70010120niversity of Dundee (UK)88
进行中（未招募）
1 期
The effect of aldosterone inhibition on proteinuria in patients with progressive renal disease.Patients with chronic nephropathy and proteinuria over 0,5 g/24 hrs are to be given an inhibitor of aldosterone. Theory tells that aldosterone plays an active role in nephropathy and if that can be inhibited patients with chronic renal diseases may prolong their pre-dialysis period of time.MedDRA version: 8.1Level: SOCClassification code 10038359Term: Renal and urinary disordersEUCTR2006-004411-21-DKOrganisation name was not entered25
已完成
不适用
The role of aldosterone in cardiovascular disease in chronic renal failureISRCTN37814228Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)200
进行中（未招募）
1 期
Suppression of the hormone aldosterone to diminish scar tissue in heart in patients with atrial fibrillatioEUCTR2013-000797-30-DKDepartment of Medical Research, Odense University Hospital, Svendborg Hospital